Intercept Pharma (ICPT) Tops Q3 EPS by 98c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharma (ICPT) Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting
November 2, 2021 8:11 AM EDTIntercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts on obeticholic acid (OCA), including a late-breaking oral presentation of long-term data in primary biliary cholangitis (PBC), will be presented at The Liver Meeting 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting will be held virtually from November 12 to November 15, 2021.
The Global PBC and UK-PBC databases have provided researchers with a wealth of information... More
